Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide for Young People

An English expert consensus follows STEP TEENS, where semaglutide reduced adolescent BMI but adverse events and policy limits still matter.

Why we wrote this. Expert agreement can be mistaken for trial evidence or national policy. This readout separates STEP TEENS results from England's implementation and guidance questions.

In this article (4 sections)
  1. What STEP TEENS tested
  2. The efficacy and safety results
  3. Why an England consensus was needed
  4. What remains uncertain

A 2026 English expert consensus paper addresses how semaglutide might be used for children and young people with obesity, but the efficacy evidence still rests heavily on STEP TEENS. In that randomized trial, adolescents assigned semaglutide plus lifestyle intervention had a 16.1% mean reduction in BMI at 68 weeks, compared with a 0.6% increase with placebo plus lifestyle intervention[2]. Consensus can help services handle practical gaps. It does not replace randomized evidence or create national guidance.

The new paper is explicitly described as expert consensus developed with a Delphi-like process and concerns semaglutide for obesity management in children and young people in England[1]. A Delphi process seeks structured agreement among experts, often through repeated rounds of questions. It can identify workable practice where evidence or policy is incomplete, but agreement is not the same as a comparative trial result.

What STEP TEENS tested

STEP TEENS enrolled 201 adolescents aged 12 to under 18 years. Eligibility required obesity, defined as BMI at or above the 95th percentile, or overweight at or above the 85th percentile plus at least one weight-related condition. All but one randomized participant had obesity[2]. The population therefore does not represent every young person with a higher body weight.

Participants were assigned in a two-to-one ratio to weekly semaglutide or placebo for 68 weeks, and both groups received lifestyle intervention. The primary endpoint was percentage change in BMI from baseline. A confirmatory secondary endpoint assessed whether participants lost at least 5% of their body weight[2]. The trial dose and escalation schedule belong to a research protocol, not instructions for unsupervised use.

Of the 201 randomized participants, 180 completed treatment. Completion was therefore high, but not universal. A trial result based on scheduled follow-up can differ from routine care, where access and adherence reflect family circumstances and service capacity. Treatment interruptions may also be less controlled.

The efficacy and safety results

Mean BMI changed by 16.1% downward with semaglutide and 0.6% upward with placebo at week 68. The estimated difference was 16.7 percentage points, with a 95% confidence interval from 13.2 to 20.3 percentage points in favor of semaglutide[2]. The size of that difference explains why the trial drew attention, but it describes a group average rather than a guaranteed individual response.

At least 5% weight loss occurred in 95 of 131 participants in the semaglutide group, or 73%, and 11 of 62 in the placebo group, or 18%. The estimated odds ratio was 14.0, with a 95% confidence interval from 6.3 to 31.0[2]. The wide interval signals uncertainty about the exact size of the odds ratio even though the between-group difference was clear.

Semaglutide also produced greater improvements in waist circumference and glycated haemoglobin. Most measured lipids and alanine aminotransferase also improved more, while high-density lipoprotein cholesterol was the stated lipid exception[2]. These were cardiometabolic measures, not evidence that the trial prevented future cardiovascular or liver disease in adolescents.

Gastrointestinal adverse events were reported in 62% of participants assigned semaglutide and 42% assigned placebo. Five participants in the semaglutide group, or 4%, developed cholelithiasis, compared with none in the placebo group. Serious adverse events occurred in 11% and 9%, respectively[2]. A benefit discussion for young people has to carry these harms alongside the BMI result.

Why an England consensus was needed

A randomized efficacy trial answers whether an intervention changed prespecified outcomes under trial conditions. It does not by itself specify referral pathways, multidisciplinary responsibilities, mental health assessment, safeguarding, consent, monitoring, or how services respond when treatment is interrupted. Those issues become especially important when care involves a child and their family.

The 2026 consensus publication signals an attempt to address those implementation questions in England[1]. Readers should distinguish that expert document from NICE technology appraisal TA910. NICE states that it was unable to recommend semaglutide for managing overweight and obesity in people aged 12 to 17 because the company did not provide an evidence submission, and the appraisal was terminated[3].

That distinction matters. A professional consensus can be informative without carrying the authority of a completed NICE recommendation. It also cannot change a medicine's legal authorization or the eligibility criteria used by a commissioned specialist service. In England, readers should check the current regulator, NICE, NHS, and local service position rather than infer access from a journal article.

Our semaglutide evidence page covers the molecule more broadly. The UK regulatory overview explains why approval, national guidance, commissioning, and local access are separate questions. None of these sources supports buying or administering semaglutide outside qualified clinical care.

What remains uncertain

STEP TEENS lasted 68 treatment weeks and was funded by the manufacturer. It cannot establish the full balance of benefit and harm across years of adolescent development. The trial also does not settle what happens to weight, metabolic measures, eating behavior, or wellbeing after prolonged discontinuation. Chronic treatment decisions need longer evidence than one major trial provides.

The published abstract reports BMI and several cardiometabolic measures, but those are not the whole experience of treatment. Quality of life, body image, stigma, disordered eating risk, family expectations, school life, and treatment burden can matter to a young person. A clinically useful pathway must consider outcomes that are not captured by a single percentage change.

Generalizability is another limit. Trial participants volunteered and met defined criteria while receiving regular follow-up. Children with complex medical conditions, severe mental health needs, unstable home circumstances, or barriers to specialist services may have been underrepresented. An average trial effect should not be presented as a promise to each family.

The evidence supports a focused conclusion: semaglutide plus lifestyle intervention reduced BMI more than placebo plus lifestyle intervention over 68 weeks in adolescents with obesity enrolled in STEP TEENS. The 2026 consensus may help English clinicians discuss implementation, but it is a different kind of evidence. Policy authority, individualized assessment, careful monitoring, and honest discussion of uncertainty remain essential[2].

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

How much did BMI change in STEP TEENS?

Mean BMI fell 16.1% with semaglutide and rose 0.6% with placebo at week 68, an estimated difference of 16.7 percentage points. Both groups received lifestyle intervention.

Did every adolescent lose at least 5% of body weight?

No. At least 5% weight loss occurred in 73% of semaglutide participants and 18% of placebo participants, so response was not universal.

Is the expert consensus the same as NICE guidance?

No. It is a journal consensus document. NICE terminated its appraisal and states that it could not recommend semaglutide for ages 12 to 17 because no company evidence submission was provided.

Sources

  1. [1]Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process. Archives of Disease in Childhood. 2026. PMID 42977490.Tier 1 · primary↩
  2. [2]Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022. PMID 36322838.Tier 1 · primary↩
  3. [3]Semaglutide for managing overweight and obesity in young people aged 12 to 17 years, terminated appraisal TA910. NICE.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars